MGMT and neoplasm: The study found that a high impact of MGMT status in patients with moderately vascularized tumors and the characterization of tumor vascularization may help to improve the estimation of responsiveness to standard-of-care treatment (temozolomide) and prognosis, rather than MGMT methylation assessment alone.